Stocktoria
ARDELYX, INC. ARDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-19
ARDELYX, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -10.1% | -8.4% | -50.8% | -122.2% | -1528.6% |
| Net margin | -15.1% | -11.7% | -53.1% | -128.9% | -1566.5% |
| FCF margin | -10.8% | -13.7% | -72.4% | -134.4% | -1529.3% |
| Return on assets | -12.3% | -9.0% | -22.2% | -35.4% | -105.5% |
| Return on equity | -36.9% | -22.6% | -39.6% | -68.3% | -191.4% |
| Debt / equity | 1.21× | 0.87× | 0.30× | 0.27× | 0.39× |
| Current ratio | 4.31 | 4.58 | 4.88 | 2.34 | 2.53 |
| Revenue growth | 22.1% | 168.1% | 138.6% | 416.6% | 33.4% |
Source: SEC EDGAR filings · CIK 0001437402 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.